Stem Cells vs PRP: Which Is Right for You?

If you've been reading about regenerative medicine for any length of time, you've already run into the two big names. PRP and stem cells. Sometimes presented as competitors. Sometimes bundled together. Almost always priced as if they were interchangeable.

They aren't. They do different work, at different depths, in different tissues, for different patients. Choosing between them is a diagnostic question, not a marketing one. This guide walks through how we make that call at Apex, what the evidence actually says, and the small handful of red flags that signal a clinic is selling rather than treating.

Most patients reading this will fit cleanly into one of three categories: a clear PRP case, a clear stem cell case, or a case where the right answer is a sequenced combination. By the end of this guide you should be able to put yourself in roughly the right bucket, and bring the right questions to a consultation.

What PRP actually is

Platelet-rich plasma is your own blood, drawn into a small tube, spun in a centrifuge, and reinjected into the tissue we want to wake up. Spinning concentrates the platelets and the growth factors they carry: PDGF, TGF-beta, VEGF, IGF-1, EGF, FGF, and others. Those proteins are the body's normal repair signal. When you sprain an ankle, platelets pool at the injury site and release these factors. PRP is a way to deliver that same signal, in higher concentration, exactly where the tissue needs it.

A few things to know up front:

It's autologous. You're the donor. Rejection isn't a concern, donor screening isn't a concern, and the regulatory category is the simplest in the regenerative space.

Concentration matters more than most patients realize. A "1.5x" PRP, which is what you'd get from a basic single-spin centrifuge, behaves very differently from a "5x" or "7x" double-spin preparation. The platelet count per microliter is the dose, and the dose has a sweet spot. Too dilute and the growth factor concentration is too low to drive a robust response. Too concentrated and you can paradoxically inhibit the same biology you're trying to activate, because hyperphysiological platelet concentrations release so many cytokines at once that the local tissue switches into a defensive rather than reparative mode.

Leukocyte content matters too. Leukocyte-poor PRP (LP-PRP), which depletes most white blood cells, is what we use for intra-articular joint work because the lower inflammatory burden produces better symptomatic and biological results in the joint environment. Leukocyte-rich PRP (LR-PRP) keeps the white cells in and is used for some tendon protocols, where a controlled inflammatory burst at a chronically silent injury site can help kick repair back on. The published literature has slowly converged on these distinctions, but you'd never know it from a clinic that delivers the same single formulation regardless of the indication.

Growth-factor signaling is also short-lived. The platelets degranulate over hours to days. The repair response they trigger builds over weeks. Patients often expect to feel something acutely; the meaningful change typically happens at four to eight weeks.

PRP is excellent at one thing: telling tissue that already has the capacity to heal that now is the time. If the tissue's repair machinery is intact, PRP gets results. If it isn't, PRP can't manufacture biology that isn't there.

What stem cell therapy actually is

The term "stem cells" gets used loosely. At Apex we mean mesenchymal stem cells (MSCs), specifically allogeneic, screened, donor-derived MSCs from umbilical cord tissue, often paired with MSC-derived exosomes from FDA-registered processors.

Three things distinguish this from PRP:

You're delivering cells, not just signals. MSCs do communicate (they release their own exosomes and cytokines), but they're also live cells that home to inflamed tissue and modulate the local environment for weeks. They take up temporary residence in the joint, the surrounding capsule, and the inflamed soft tissue, releasing repair signaling that continues for far longer than a single dose of platelets ever could.

The source isn't you. That's a feature, not a bug. Young donor cells from screened umbilical tissue are dramatically more potent than the same cells harvested from an adult patient's hip or belly fat. (More on this in the allogeneic vs autologous guide.) The cells we use come from screened, healthy, full-term mothers who consent to use of tissue that would otherwise be discarded after a planned cesarean delivery. The tissue undergoes a battery of infectious disease screening (HIV, hepatitis B and C, HTLV, syphilis, CMV, West Nile, Zika, and others) plus genetic testing and sterility validation before it ever reaches a treatment room.

The biology is deeper. Stem cells modulate the immune environment, support paracrine repair, and in cartilage-poor joints can shift the inflammatory state of the joint for months. The current model is that MSCs operate primarily through immunomodulation and paracrine signaling rather than by differentiating into new cartilage cells themselves. That's an important distinction, because a lot of the early marketing in this space implied "we grow you new cartilage," and the actual mechanism is closer to "we quiet the inflammatory storm that's keeping your tissue from healing the cartilage it has."

If PRP is a megaphone for the body's repair signal, MSC therapy is bringing in an outside crew with their own tools and instructions.

A head-to-head comparison

How PRP actually gets made and delivered

Here's what happens when you come in for a PRP injection at Apex, so you can compare against what other clinics describe:

The visit starts with a quick check-in and a confirmation of the indication and side. We draw 30 to 60 mL of blood into specialized tubes, depending on the joint count and the formulation we're using that day. The tubes go into a centrifuge for a controlled spin cycle. We use a closed double-spin system that lets us target the platelet concentration we want for the indication rather than just taking what we get.

While the centrifuge is running, we set up the procedure room: sterile drapes, the ultrasound machine, the injection tray, local anesthetic. The injection itself is image-guided every time. We confirm the needle tip is in the target structure (intra-articular for joints, intra-tendinous for tendinopathy) before delivering the PRP. The injectate is small in volume (usually 4 to 6 mL per joint), so accuracy of placement matters enormously.

Post-injection, you'll have 24 to 72 hours of local soreness. This is normal and predictable. We avoid NSAIDs for 5 to 7 days post-procedure because the anti-inflammatory effect actually works against the controlled inflammatory cascade that PRP is trying to trigger. Acetaminophen and ice are fine. We have you reduce loading on the injected joint or tendon for the first 7 days, then progressively return to activity.

Most patients notice gradual improvement starting in week three or four. Peak effect lands at 8 to 12 weeks. We see you back at 12 weeks for re-evaluation, with formal outcome measures (pain score, function score) documented in your chart.

How a stem cell protocol actually gets made and delivered

A stem cell protocol differs from PRP at several points in the chain.

There's no blood draw. The cells are an off-the-shelf, lot-controlled allogeneic product. We confirm the lot documentation matches your chart before we open the vial. The cell count, source, processing facility, and lot expiration date are documented.

The injectate volume is typically larger (5 to 12 mL depending on joint and protocol), and the dose is documented in cell count, not just volume. A typical knee protocol might deliver 1.5 to 2.0 x 10^7 viable MSCs with an exosome adjunct, image-guided into the intra-articular space.

Post-procedure soreness tends to be a bit more pronounced than PRP, often 48 to 96 hours, occasionally including a transient inflammatory flare in the treated joint at 24 to 72 hours that resolves on its own. This isn't a sign of rejection or a complication; it's the local immune system noticing the dose and engaging with it. We tell patients to expect it so they're not anxious about it.

The recovery curve is slower. Patients typically don't feel meaningful change in the first 4 to 6 weeks. Improvement starts to surface around week 8 to 10, builds through month 4, and continues to deepen through months 6 to 12. We see patients at 6 weeks (early assessment), 12 weeks (formal re-evaluation), and 6 months (peak-effect assessment). At 12 months we make a decision about whether maintenance is appropriate.

When PRP is usually the right tool

We lean PRP when:

The patient has early or moderate osteoarthritis with intact joint space on imaging. Kellgren-Lawrence grade I to II, sometimes grade III if the cartilage is still meaningfully present.

The injury is a tendon problem: rotator cuff tendinopathy, lateral or medial epicondylitis (tennis or golfer's elbow), gluteal tendinopathy, plantar fasciitis, patellar tendinopathy. The evidence base for PRP in tendinopathy is robust, particularly for lateral epicondylitis where multiple RCTs have shown durable improvement compared to corticosteroid injection.

The condition is a partial ligament or muscle strain that has stalled, often around the 12-week mark. The classic case is a high-level athlete with a chronic adductor or hamstring issue that's responded incompletely to PT.

Cost or financing constraints make PRP a more realistic option, and the indication is reasonable. We won't recommend a treatment we don't think will work, but if PRP and stem cells are both reasonable options for a given indication and the patient can't comfortably afford the cellular protocol, the right answer is often to start with PRP and reassess.

We want to prime the tissue before, or maintain it after, a stem cell protocol. PRP-first, MSC-second sequencing has both biological logic and increasingly emerging clinical support.

PRP is also a sane first step for patients who want to try the most conservative regenerative option before committing to the bigger one. It's not the cheapest path long-term if you ultimately need cellular therapy, but it's a defensible step if the indication and the patient's preferences both support it.

When stem cell therapy is usually the right tool

We lean stem cells when:

The patient has moderate-to-severe osteoarthritis with cartilage loss visible on MRI. Kellgren-Lawrence grade III to early grade IV with some preserved joint space, where the cellular protocol's immune-modulating and paracrine effects can change the joint environment in a way PRP can't.

Previous PRP rounds have produced partial but incomplete relief. The patient responded to the signaling layer but needs a deeper biological effect to consolidate the gain.

The clinical picture suggests systemic inflammation contributing to local degeneration (and an IV component may be appropriate). Some patients show up with multifocal joint complaints, fatigue, and labs that suggest a low-grade systemic inflammatory state. A targeted joint injection plus a careful evaluation of the systemic picture, sometimes including an IV protocol, fits this patient better than serial PRP at multiple sites.

The patient is considering joint replacement and wants to honestly explore delaying or avoiding it. (See our guide on regenerative therapy and surgery.) The "gap year" use case is one of the clearest wins for cellular therapy. A 55-year-old with moderate knee OA who wants to delay replacement for two to four years is often well-served by a stem cell and exosome protocol with sensible activity modification.

The tissue is deeper and slower to heal: a chronic disc-related lower back, a hip with avascular changes, certain neurologic indications under research-grade protocols.

What the evidence actually says

The randomized trial literature on PRP for knee osteoarthritis is mixed. The 2021 JAMA paper by Bennell and colleagues found PRP no better than saline at 12 months on the primary outcome, which surprised a lot of clinicians who had been using PRP confidently for a decade. Other large trials and meta-analyses, especially those using leukocyte-poor formulations and high platelet concentrations, show clear superiority over hyaluronic acid and reasonable signal over saline at shorter follow-up.

The honest read: PRP works when the formulation, concentration, indication, and delivery are right. It doesn't work when they aren't. A clinic using a generic single-spin preparation, with no attention to leukocyte content or concentration, and delivering it blind to a joint that wasn't really the right indication, has been responsible for a lot of the negative outcomes in the literature. That's a quality problem, not necessarily a biology problem.

For tendinopathy, the PRP literature is more consistent. Lateral epicondylitis in particular has multiple positive RCTs showing PRP superiority over corticosteroid injection at 6 and 12 months, with the steroid arms showing the well-described "rebound" pattern of early relief followed by long-term tendon quality decline.

The MSC literature for knee OA is more consistent than the PRP literature in moderate disease. Recent meta-analyses pooling 15 to 20 randomized trials show meaningful pain and function improvement over saline and over hyaluronic acid, with effects sustained at 12 months. The signal is strongest for moderate OA, weaker for end-stage bone-on-bone. Cell source matters across studies; allogeneic umbilical and Wharton's jelly cells consistently produce the largest effects.

For shoulder pathology, both PRP and MSC protocols have growing evidence, with the strongest signal for PRP in rotator cuff tendinopathy and chronic full-thickness tears under a certain size threshold. For hip OA, both modalities have smaller evidence bases than knee, but the clinical experience aligns reasonably with the knee data: cells outperform plasma in moderate-to-severe disease, plasma is reasonable in early-stage and tendon-mediated cases.

For more on how to read these studies yourself, see Reading the research: a patient's primer.

A decision walkthrough by indication

For readers who want a more concrete map of how we think about specific indications, here's the rough decision logic. This is not a substitute for a workup, but it should orient you.

Knee osteoarthritis, KL grade I to II. Conservative care first (PT, weight management, activity modification). If injection-level treatment is warranted, PRP is the usual right answer. Cellular therapy is more than you need at this stage.

Knee osteoarthritis, KL grade III. This is the most common cellular-therapy candidate population. Cellular protocols outperform PRP in this range. If cost is a barrier, PRP is still a reasonable starting point with a plan to escalate if response is incomplete.

Knee osteoarthritis, KL grade IV. Surgical consultation. Cells don't reverse bone-on-bone disease, and we won't pretend they do.

Rotator cuff tendinopathy without full-thickness tear. PRP first. Tendon environment responds well to LR-PRP; the tendon has the cellular machinery for repair, it just needs the signal.

Rotator cuff partial-thickness tear under 50% thickness. PRP first, with a real shot at avoiding surgical repair.

Rotator cuff full-thickness tear. Surgical consultation. Cellular augmentation at the repair site is a reasonable adjunct, but the structural problem comes first.

Lateral epicondylitis (tennis elbow). PRP. Strong evidence base, predictable response, much better long-term tendon quality than steroid.

Patellar tendinopathy ("jumper's knee"). PRP, often combined with a shockwave course for the chronic recalcitrant cases.

Hip osteoarthritis, moderate. Cellular therapy is the stronger choice. The hip joint is deeper and harder to influence with the briefer signaling of PRP.

Plantar fasciitis, chronic. Shockwave first if untried, then PRP if needed. Cellular therapy is overkill for most plantar fasciitis.

Disc-mediated lumbar pain, moderate. This is a more nuanced case. Some patients are candidates for a cellular protocol delivered into the disc or paraspinal soft tissue. Others are better served by procedural pain management or surgical consultation. We don't pretend cellular therapy is the answer for everyone here.

Avascular necrosis of the hip, early stage. Cellular therapy has emerging support for delaying or avoiding hip replacement when the disease is caught early. We coordinate with orthopedic surgery on these cases.

Multifocal joint pain with systemic symptoms. Workup first. If the underlying picture is an undiagnosed systemic inflammatory disease, the right answer is a rheumatology referral, not a stem cell injection.

The combination question

Patients often ask whether we can "just do both." Sometimes yes, sometimes no, and the why matters.

We sequence PRP and stem cells when:

The indication suggests both a need for immediate signaling (PRP) and a deeper biological reset (cellular therapy). A common case is moderate knee OA with a co-existing patellar tendinopathy.

The patient wants the strongest available protocol and the financial calculus works. Combined protocols are not "twice as effective" as either alone, but they layer well in the right cases.

The tissue benefits from priming before the larger procedure. A PRP injection 4 to 6 weeks before a cellular procedure can improve the local vascular and signaling environment.

We don't combine them when:

The right answer is one or the other and combining is a price upsell rather than a clinical advantage. Some clinics default to combined protocols for revenue reasons. We don't.

The patient is paying for the combination because they think more is better, in a case where the simpler protocol is the right answer.

The cost question, plainly

At Apex, PRP runs $1,200 to $1,500 per joint per visit, with each additional same-visit joint at $800; series of three protocols are also available. Stem cell protocols run $3,200 to $4,800 for MSC alone and $6,200 to $8,000 with exosomes, both of which include a PRP draw and a red light therapy course at no extra charge. Bilateral and multi-joint protocols are priced at twice the single-joint cost less a 10% multi-joint discount. Neither is reimbursed by commercial insurance in 2026.

A clinic that quotes you a five-figure "package" priced by visit count, before seeing your imaging or asking what you've tried, is selling. A clinic that maps the protocol to your imaging and your goals, and tells you which option is actually the right tool, is practicing medicine.

We publish full pricing in the coverage, cost, and financing guide.

The placebo question

Patients sometimes ask me, frankly: "Isn't a lot of this just placebo?" It's a fair question and it deserves a non-defensive answer.

Placebo effects in osteoarthritis injection studies are real and large. Saline injections in joint trials typically produce 20 to 30 percent pain improvement at short follow-up, which is a meaningful share of the absolute effect any active treatment will show. This is part of why we care so much about controlled trials with saline arms, not just comparisons to "natural history."

That said, the durable signal at 6, 12, and 24 months in the better cellular trials is well above any plausible placebo effect, and the structural changes visible on MRI in some cohorts are not a placebo finding. PRP's evidence base is more mixed precisely because the placebo subtraction matters more at the modest effect sizes PRP produces in some indications.

The right way to think about it: a good outcome from a regenerative procedure is partly a true biological effect, and partly the well-documented placebo response that any reasonable injection produces. We aim to deliver patients who get both, with the biological effect doing the larger and more durable share of the work.

What you can do before your consultation

A few things that make our consultation more useful, and your decision better:

Get your imaging together. If you have an MRI or weight-bearing X-ray from the last 24 months, bring it on disc or share it through our patient portal. If you don't, we'll order what we need, but having it saves a step.

Write your goal in one sentence. "I want to walk to the mailbox without pain by Christmas" is more useful than "I want my knee to feel better." Specific goals drive specific protocols.

List what you've tried, honestly. Including the things that didn't help. Including any injections you've had elsewhere. We're not judging; we're trying to figure out what hasn't worked so we don't repeat it.

Bring a list of medications and supplements. NSAIDs, blood thinners, certain herbal supplements, and steroids all affect either the procedure or the response. We need to know.

Bring a second pair of ears if you can. A spouse, a parent, an adult child. Decisions made about your own joints under pain conditions are easier with another person who can listen, take notes, and ask the questions you forget.

How we decide at Apex

Every patient considering either protocol gets the same workup before we quote anything: history and exam, imaging review (or new imaging if it's missing or stale), targeted functional labs when systemic inflammation is in the picture, and a discussion of goals. The protocol falls out of that workup. If the right answer is PRP, we'll tell you. If the right answer is a stem cell protocol, we'll tell you. If the right answer is to see a surgeon, or to do six weeks of physical therapy first, or to do nothing yet, we'll tell you that too.

If you'd like to start that conversation, request a consultation or call us at (972) 768-2328.

A short note from Dr. Abdullah

Patients ask me which is "better" almost every week. The honest answer is that the comparison only makes sense once we know what we're treating, what the tissue looks like, and what the patient is actually trying to do with their next 10 years. A 52-year-old who wants to keep skiing has a different calculus than a 78-year-old who wants to walk to the mailbox without pain. Both have real options. Both deserve the protocol that fits, not the one priced highest.

Apex sits in Southlake, just off Kirkwood Boulevard. We see patients from across the DFW metroplex and from out of state. Our consultation fee is flat regardless of whether you become a treatment patient, which removes the incentive to recommend a protocol you don't need. If we tell you stem cells are the right call, it's because we think they are, not because we'd rather sell you a $6,000 protocol than a $1,200 one.